|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Abilify
|
|
gptkbp:approves
|
gptkb:2013
|
|
gptkbp:brand
|
gptkb:Abilify
|
|
gptkbp:clinical_trial
|
prevent relapse
Phase III
maintenance treatment
|
|
gptkbp:contraindication
|
hypersensitivity to aripiprazole
|
|
gptkbp:dosage_form
|
long-acting injectable
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:education
|
recognizing side effects
importance of adherence
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
sustained-release
injectable suspension
|
|
gptkbp:frequency
|
once a month
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abilify Maintena
|
|
gptkbp:ingredients
|
gptkb:aripiprazole
|
|
gptkbp:interacts_with
|
CY P2 D6 inhibitors
CY P3 A4 inhibitors
|
|
gptkbp:is_used_for
|
schizophrenia
bipolar disorder
|
|
gptkbp:lifespan
|
approximately 75 hours
|
|
gptkbp:manager
|
intramuscular injection
|
|
gptkbp:manufacturer
|
gptkb:Otsuka_Pharmaceutical
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
pre-filled syringe
|
|
gptkbp:population
|
adults
adolescents
|
|
gptkbp:premiered_on
|
2 to 3 weeks
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:price
|
varies by insurance
|
|
gptkbp:products
|
gptkb:Abilify
aripiprazole orals
|
|
gptkbp:safety_features
|
regular follow-up visits
|
|
gptkbp:side_effect
|
anxiety
nausea
drowsiness
insomnia
weight gain
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:website
|
deltoid muscle
gluteal muscle
|